These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28658094)

  • 1. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.
    Patel PJ; Hayward KL; Rudra R; Horsfall LU; Hossain F; Williams S; Johnson T; Brown NN; Saad N; Clouston AD; Stuart KA; Valery PC; Irvine KM; Russell AW; Powell EE
    Medicine (Baltimore); 2017 Jun; 96(26):e6761. PubMed ID: 28658094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
    Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
    Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.
    Williams KH; Burns K; Constantino M; Shackel NA; Prakoso E; Wong J; Wu T; George J; McCaughan GW; Twigg SM
    J Diabetes Complications; 2015; 29(8):1240-7. PubMed ID: 26297218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
    Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
    Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
    PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.
    Patel PJ; Smith D; Connor JP; Horsfall LU; Hayward KL; Hossain F; Williams S; Johnson T; Stuart KA; Brown NN; Saad N; Clouston AD; Irvine KM; Russell AW; Valery PC; Powell EE
    Can J Gastroenterol Hepatol; 2017; 2017():7927685. PubMed ID: 29226116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.
    Julián MT; Ballesta S; Pera G; Pérez-Montes de Oca A; Soldevila B; Caballería L; Morillas R; Expósito C; Martínez-Escudé A; Puig-Domingo M; Franch-Nadal J; Torán P; Cusi K; Julve J; Mauricio D; Alonso N
    Front Endocrinol (Lausanne); 2022; 13():1051958. PubMed ID: 36714592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO).
    Nabi O; Boursier J; Lapidus N; Mathurin P; de Ledinghen V; Petit JM; Goldberg M; Zins M; Lacombe K; Serfaty L
    Liver Int; 2022 Mar; 42(3):595-606. PubMed ID: 35066992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD.
    Dajani AI; Abu Hammour AM; Zakaria MA; Al Jaberi MR; Nounou MA; Semrin AI
    Arab J Gastroenterol; 2015; 16(3-4):99-104. PubMed ID: 26589371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
    Prasetya IB; Hasan I; Wisnu W; Rumende CM
    Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review.
    Käräjämäki AJ; Hukkanen J; Ukkola O
    Ann Med; 2018 Aug; 50(5):371-380. PubMed ID: 29929399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
    Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
    Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective.
    Rhee EJ
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):226-233. PubMed ID: 31565874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications.
    Yan LH; Mu B; Guan Y; Liu X; Zhao N; Pan D; Wang SZ
    J Diabetes Investig; 2016 Nov; 7(6):889-894. PubMed ID: 27181828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.